TherapeuticsMD, Inc. (NASDAQ:TXMD)‘s stock had its “outperform” rating restated by investment analysts at Cowen and Company in a research note issued to investors on Monday. They currently have a $16.00 target price on the stock, up from their prior target price of $13.00. Cowen and Company’s target price would suggest a potential upside of 152.21% from the company’s current price.

Several other equities analysts have also issued reports on the company. Oppenheimer Holdings, Inc. set a $10.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research note on Monday, October 16th. Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of TherapeuticsMD in a research note on Tuesday, September 26th. Deutsche Bank AG reaffirmed a “buy” rating and set a $10.00 price target on shares of TherapeuticsMD in a research note on Wednesday, September 13th. Morgan Stanley started coverage on TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective for the company. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a report on Monday, September 4th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $15.25.

Shares of TherapeuticsMD (NASDAQ TXMD) traded up $1.98 on Monday, hitting $6.34. The stock had a trading volume of 19,004,823 shares, compared to its average volume of 2,642,326.

ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD, Inc. (TXMD) Rating Reiterated by Cowen and Company” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-rating-reiterated-by-cowen-and-company/1682922.html.

In related news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was acquired at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the completion of the acquisition, the director now owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 23.92% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TXMD. Teachers Advisors LLC increased its holdings in TherapeuticsMD by 1.4% in the first quarter. Teachers Advisors LLC now owns 639,602 shares of the company’s stock valued at $4,605,000 after purchasing an additional 9,077 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock worth $70,574,000 after acquiring an additional 515,992 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock worth $9,213,000 after acquiring an additional 117,660 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock worth $4,510,000 after acquiring an additional 60,229 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock worth $28,105,000 after acquiring an additional 253,237 shares in the last quarter. Institutional investors and hedge funds own 71.40% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.